Anti-CD45RB antibody [MEM-55], prediluted (FITC) (ab18239)


  • Product nameAnti-CD45RB antibody [MEM-55], prediluted (FITC)
    See all CD45RB primary antibodies
  • Description
    Mouse monoclonal [MEM-55] to CD45RB, prediluted (FITC)
  • ConjugationFITC. Ex: 493nm, Em: 528nm
  • SpecificityMouse monoclonal [MEM-55] to CD45RB (ab18239) recognizes a siliadase-sensitive epitope of CD45RB antigen.
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Thymocytes and T lymphocytes (Human).



Our Abpromise guarantee covers the use of ab18239 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notesFlow Cyt: 1/5. Use 20µl per 100µl whole blood.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
    • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
      Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
    • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
      Contains 2 fibronectin type-III domains.
      Contains 2 tyrosine-protein phosphatase domains.
    • DomainThe first PTPase domain interacts with SKAP1.
    • Post-translational
      Heavily N- and O-glycosylated.
    • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
    • Information by UniProt
    • Database links
    • Alternative names
      • B220 antibody
      • CD 45 antibody
      • CD45 antibody
      • CD45 antigen antibody
      • CD45R antibody
      • GP180 antibody
      • L-CA antibody
      • LCA antibody
      • Leukocyte common antigen antibody
      • LY5 antibody
      • Lyt4 antibody
      • Protein tyrosine phosphatase receptor type C antibody
      • Protein tyrosine phosphatase, receptor type, c polypeptide antibody
      • Ptprc antibody
      • PTPRC_HUMAN antibody
      • Receptor-type tyrosine-protein phosphatase C antibody
      • T200 antibody
      • T200 glycoprotein antibody
      • T200 leukocyte common antigen antibody
      see all

    References for Anti-CD45RB antibody [MEM-55], prediluted (FITC) (ab18239)

    ab18239 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab18239.
    Please use the links above to contact us or submit feedback about this product.